美国Agios Pharmaceuticals 
Agios Pharmaceuticals是一家独立的未公开上市生物制药公司，致力于在新兴的癌代谢领域发现并开发出新型治疗方案。为了支持并推进这些努力，Agios已经建立了一个集生物学、代谢组学、生物化学和信息学于一体的强大平台，为靶标与生物标记的确定提供支持。

迄今为止，Agios已经组建了一支世界级科研团队，建立了规模最大的癌代谢研究实验室，并创立了一个致力于研究新型癌症疗法的新兴复方药开发渠道。该公司的创始人与科研顾问都是癌代谢领域的核心思想领导者，负责该领域的主要进展、见解与发现工作。Agios Pharmaceuticals位于马萨诸塞州坎布里奇，由Third Rock、Flagship和ARCH Venture Partners提供资金。
首家致力于研发通过生化代谢的方式来阻止癌细胞的扩散，并最终治愈的生物医药公司Agios Pharmaceuticals宣布，其获得了3300万美元的A轮融资。 资金将用于搭建一个平台，以加速治疗癌症药物的研发过程。Third Rock Ventures、Flagship Ventures、ARCH Venture Partners联合主导了此次投资。

Agios is a biopharmaceutical company at the forefront of one of the most exciting new areas of cancer research: cancer metabolism. Cancer metabolism represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth.

Over the past few decades cancer research has focused on complex tumor signaling originating from oncogenes and tumor suppressor genes; the new field of cancer metabolism shows many of these signals are actually modulating the metabolic functioning of cancer cells. As a result, the intersection of these two fields of research — cancer and metabolism — represents an important and novel approach to treating cancer. The new understanding of a fundamental mechanism of cancer survival represents a new, powerful Achilles’ Heel to target this deadly disease.

Agios Pharmaceuticals is developing a deep pipeline of drug candidates that disrupt the growth and survival of cancer based on unique insights of the founders, scientific advisory board as well as building on decades of research in the fields of oncology and metabolism.

The company’s initial focus is cancer, particularly targeting three key metabolic pathways — glycolysis (sugar metabolism), fatty acid metabolism, and autophagy (self-metabolism). Agios’ primary focus is in oncology, but the company’s platform will also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases.